Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma

NCT07297212 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07297212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-site, Open-label Trial Evaluating the Safety and Efficacy of Pumitamig and Bevacizumab as Monotherapy and Pumitamig in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2026
Completion date
July 31, 2029
Enrollment
75 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma